- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01371578
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS US 256 0124)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In September 2011, the FDA requested that Gilead make several major changes to this study because of side effects experienced by two patients in other Gilead studies.
In 2 HCV-infected people that were given tegobuvir with another experimental medication plus interferon and ribavirin, big reductions in the number of white blood cells, red blood cells and platelets were seen. Because these cases might have been related to tegobuvir when given with interferon, ribavirin and another direct antiviral agent, tegobuvir is no longer being given to people with these other medications in this study.
As a result, the study is now open label which means both you and your study doctor will know the medication you will be receiving and Arms 1 and 3 have been discontinued from the study.
All subjects enrolled in the study as of September 2nd 2011 will receive Response Guided Therapy (RGT) with both GS-5885 and GS-9451 plus PEG and RBV.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Dothan, Alabama, Estados Unidos, 36305
- Digestive Health Specialists of the Southeast
-
Montgomery, Alabama, Estados Unidos, 36116
- Alabama Liver and Digestive Specialists
-
-
California
-
Beverly Hills, California, Estados Unidos, 90211
- California Liver Institute
-
La Jolla, California, Estados Unidos, 92037
- Scripps Clinic
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Medical Center
-
San Diego, California, Estados Unidos, 92123
- Medical Associates Research Group
-
San Diego, California, Estados Unidos, 92154
- Kaiser Permanente
-
San Diego, California, Estados Unidos, 92015
- RESEARCH and EDUCATION, INC
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Denver
-
Englewood, Colorado, Estados Unidos, 80110
- South Denver Gastroenterology
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34209
- Bach and Godofsky Infectious Diseases
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
Orlando, Florida, Estados Unidos, 32803
- Orlando Immunology Center
-
Wellington, Florida, Estados Unidos, 33414
- South Florida Center of Gastroenterology, LLC
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30309
- Digestive Healthcare of Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University, Infectious Disease Clinic
-
Decatur, Georgia, Estados Unidos, 30033
- Dekalb Gastroenterology
-
Marietta, Georgia, Estados Unidos, 30060
- Gastrointestinal Specialists of Georgia PC
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University
-
Indianapolis, Indiana, Estados Unidos, 46237
- Indianapolis Gastroenterology Research Foundation
-
-
Kentucky
-
Bowling Green, Kentucky, Estados Unidos, 42101
- Graves Gilbert Clinic
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Gastroenterology Associates, LLC
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21229
- Digestive Disease Associates, PA
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Beth Israel Deaconess Medical Center
-
Worcester, Massachusetts, Estados Unidos, 01608
- Partners in Internal Medicine, P.C.
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Health System
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39202
- Gastrointestinal Associates, PA
-
Tupelo, Mississippi, Estados Unidos, 38801
- Digestive Health Specialists, PA
-
-
New Jersey
-
Hillsborough, New Jersey, Estados Unidos, 08844
- ID Care 105
-
Morristown, New Jersey, Estados Unidos, 07960
- Atlantic Research Affiliates, LLC
-
-
New Mexico
-
Santa Fe, New Mexico, Estados Unidos, 87505
- Southwest CARE Center
-
-
New York
-
Binghamton, New York, Estados Unidos, 13903
- Binghamton Gastroenterology
-
Manhasset, New York, Estados Unidos, 11030
- North Shore University Hospital
-
New York, New York, Estados Unidos, 10016
- Concorde Medical Group
-
New York, New York, Estados Unidos, 10021
- Cornell University Gastroenterology & Hepatology
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Asheville Gastroenterology Associates, P.A.
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Fayetteville, North Carolina, Estados Unidos, 28304
- Cumberland Research Associates, LLC
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- University of Cincinnati
-
-
Oklahoma
-
Tulsa, Oklahoma, Estados Unidos, 74104
- Options Health Research, LLC
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- University Gastroenterology
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Memphis Gastroenterology Group
-
Nashville, Tennessee, Estados Unidos, 37205
- Nashville Medical Research Institute
-
Nashville, Tennessee, Estados Unidos, 37211
- Nashville Gastrointestinal Specialists, Inc
-
Nashville, Tennessee, Estados Unidos, 37203
- Columbia Medical Group, The Frist Clinic
-
-
Texas
-
Arlington, Texas, Estados Unidos, 76012
- The North Texas Research Institute
-
Dallas, Texas, Estados Unidos, 75246
- Baylor University Medical Center
-
Houston, Texas, Estados Unidos, 77005
- Kelsey Research Foundation
-
Houston, Texas, Estados Unidos, 77030
- Research Specialists of Texas
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Metropolitan Research
-
Norfolk, Virginia, Estados Unidos, 23502
- Digestive and Liver Disease Specialists
-
Richmond, Virginia, Estados Unidos, 23249
- Liver Institute of Virginia
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Virginia Mason Medical Center, Digestive Disease Institute
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion de Investigacion de Diego
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female, aged from 18 to 70 years old, inclusive
- Chronic HCV infection for at least 6 months prior to Baseline
- Subjects must have liver biopsy results (≤ 3 years prior to screening) indicating the absence of cirrhosis.
- Monoinfection with HCV genotype 1
- HCV RNA > 10^4 IU/mL at Screening
- Prior treatment and adherence (as defined by receiving at least 80% of the prescribed treatment) with one course of a pegylated interferon-alfa (Pegasys or Peg-Intron) and RBV
The subject's medical records must include sufficient detail of prior treatment with pegylated interferon-alfa and RBV (start/stop dates and viral response) to allow for categorization of prior response as either
- Non-Responder: Subject did not achieve undetectable HCV RNA levels during or at the end of a treatment period of at least 12 weeks duration. Within Nonresponders, subjects will be further defined as Null or Partial Responders if they had < 2 log10 or ≥ 2 log10 reduction, respectively, in HCV RNA during the first 12 weeks of treatment
- Responder: Subject achieved undetectable HCV RNA during treatment. Within Responders, subjects will be further defined as Relapsers if they had undetectable HCV RNA at the end of at least 42 weeks of treatment but detectable HCV RNA levels observed within 1 year of the end of treatment and Breakthrough subjects if they achieved undetectable HCV RNA levels during the treatment period but detectable HCV RNA at the end of treatment.
- No prior treatment with an oral HCV antiviral (exclusive of RBV).
- Body mass index (BMI) 18-36 kg/m2, inclusive.
- Screening ECG without clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia's formula) ≤ 450 msec for males and ≤ 470 msec for females
- Creatinine clearance ≥ 50 mL/min.
- Agree to use two forms of highly effective contraception for the duration of the study and for 6 months after the last dose of study medication. Females of childbearing potential must have a negative pregnancy test at Screening and Baseline
Exclusion Criteria:
- Discontinued prior treatment with pegylated interferon-alfa and RBV due to an adverse event, toxicity reasons or were lost to follow-up.
- Exceed defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH)
- Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), HIV, hepatitis B virus (HBV), or another HCV genotype, hepatocellular carcinoma or other malignancy (with exception of certain skin cancers), hemoglobinopathy, retinal disease, or are immunosuppressed.
- Current use of amphetamines, cocaine, opiates (e.g., morphine, heroin), or ongoing alcohol abuse are excluded. Subjects on stable methadone are excluded, however stable buprenorphine maintenance treatment for at least 6 months is not exclusionary
- Receiving any of the prohibited concomitant medications.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm 2
AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food. PM Dosing: RBV with food. PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences. |
30 mg active tablet
two active 100 mg tablets
peginterferon alfa-2a (solution for injection) 180 µg/week
ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Sustained Virologic Response (SVR)
Periodo de tiempo: through 24 weeks of off-treatment follow-up
|
To evaluate antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < Lower Limit of Quantification (LLoQ) 24 weeks post-treatment) of response guided therapy (RGT) with GS-9451 + GS-5885, with peginterferon alfa-2a (PEG) and ribavirin (RBV) in treatment-experienced subjects.
|
through 24 weeks of off-treatment follow-up
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Sustained Virologic Response(SVR) of each regimen administered for 24 to 48 weeks
Periodo de tiempo: Weeks 1, 2, 4, 8, 12, 16, 20, 24, 36, 48 and at 4 and 12 weeks off-treatment
|
To evaluate antiviral efficacy as measured by SVR for 24 or 48 weeks of treatment with GS-5885, GS-9451, PEG, RBV.
|
Weeks 1, 2, 4, 8, 12, 16, 20, 24, 36, 48 and at 4 and 12 weeks off-treatment
|
Safety and Tolerability
Periodo de tiempo: through 24 to 48 week treatment period and up to 24 weeks of off-treatment follow-up
|
To evaluate the safety and tolerability of treatment with GS-5885, GS-9451, PEG & RBV administered for 24 or 48 weeks.
Safety endpoints will be summarized as the number (proportion) of subjects with events or abnormalities for categorical values or as an 8-number summary (n, mean, standard deviation, median, Q1, Q3, minimum, maximum) for continuous data by treatment arm.
|
through 24 to 48 week treatment period and up to 24 weeks of off-treatment follow-up
|
Characterize the viral dynamics of GS-5885, GS-9451 when administered in combination with PEG and RBV
Periodo de tiempo: Through Week 2 of therapy
|
HCV RNA levels, pharmacokinetics, and viral sequencing
|
Through Week 2 of therapy
|
Characterize the pharmacokinetics of GS-5885 and GS-9451 when administered in combination with PEG and RBV
Periodo de tiempo: Through Week 2 of therapy
|
Plasma concentrations of the study drug over time will be summarized using descriptive statistics.
Pharmacokinetic parameters (Cmax, Tmax, Clast, Tlast, Ctau, λz, AUCtau, and T½) will be listed and summarized for GS-5885 and GS-9451, using descriptive statistics (eg, sample size, arithmetic mean, geometric mean, % coefficient of variation, standard deviation, median, minimum, and maximum).
|
Through Week 2 of therapy
|
Emergence of Viral Resistance
Periodo de tiempo: through 24 to 48 week treatment period and up to 24 weeks of off-treatment follow-up
|
To characterize the viral resistance to GS-5885 and GS 9451tegobuvir when administered in combination with PEG and RBV.
|
through 24 to 48 week treatment period and up to 24 weeks of off-treatment follow-up
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Infecciones por virus de ARN
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Hepatitis Crónica
- Hepatitis
- Hepatitis A
- Hepatitis C
- Enfermedades virales
- Hepatitis C Crónica
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Antimetabolitos
- Ribavirina
- Peginterferón alfa-2a
- Ledipasvir
Otros números de identificación del estudio
- GS-US-256-0124
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hepatitis C Crónica
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC) | Infección viral de la hepatitis CEstados Unidos, Nueva Zelanda
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 4 | Infección viral de la hepatitis CEstados Unidos
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC)Estados Unidos, Australia, Canadá, Francia, Alemania, Nueva Zelanda, Puerto Rico, España, Reino Unido
-
AbbVieTerminadoVirus de la hepatitis C | Virus de la hepatitis C crónica
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
Humanity and Health Research CentreBeijing 302 HospitalTerminadoInfección crónica por hepatitis CPorcelana
-
University Health Network, TorontoTerminadoInfección crónica por hepatitis CCanadá
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos, Puerto Rico
Ensayos clínicos sobre GS-5885 tablet
-
Gilead SciencesTerminadoHepatitis C CrónicaEstados Unidos, Australia, Canadá, Nueva Zelanda
-
Gilead SciencesTerminadoInfección por VHCEstados Unidos
-
Gilead SciencesTerminadoHepatitis C CrónicaNueva Zelanda
-
Gilead SciencesTerminado
-
Gilead SciencesTerminado
-
Gilead SciencesTerminadoInfección crónica por VHCJapón
-
Gilead SciencesTerminadoInfección crónica por VHCEstados Unidos
-
Gilead SciencesTerminado
-
Gilead SciencesTerminadoInfección por el virus de la hepatitis CJapón
-
Gilead SciencesTerminadoChronic Genotype 4 HCV | Chronic Genotype 5 HCVFrancia